Navigation Links
FDA Approves Duramed's LoSEASONIQUE(R) Oral Contraceptive
Date:10/27/2008

p>

About LoSEASONIQUE(R)

LoSEASONIQUE(R) is a lower dose extended cycle oral contraceptive indicated for the prevention of pregnancy. The clinical data supporting the LoSEASONIQUE(R) NDA resulted from a 12-month, multi-centered, open label clinical trial that concluded in June 2007. The clinical trial involved over 2,100 female subjects between the ages of 18 and 41 at 56 sites throughout the United States, and subjects completed an equivalent of nearly 21,000 28-day cycles of exposure.

The most common adverse events in the clinical trial were headache, irregular and/or heavy uterine bleeding, dysmenorrhea, nausea and/or vomiting, and back pain.

Important Information About Oral Contraceptives

It is estimated that more than 16 million women currently take oral contraceptives in the United States. Oral contraceptives are not for every woman. Serious as well as minor side effects have been reported with the use of hormonal contraceptives. Serious risks include blood clots, stroke, and heart attack. Cigarette smoking increases the risk of serious cardiovascular side effects, especially in women over 35 years. Oral contraceptives do not protect against HIV infection (AIDS) and other sexually transmitted diseases.

About Barr Pharmaceuticals, Inc.

Barr Pharmaceuticals, Inc. is a global specialty pharmaceutical company that operates in more than 30 countries worldwide and is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients. A holding company, Barr operates through its principal subsidiaries: Barr Laboratories, Inc., Duramed Pharmaceuticals, Inc. and PLIVA d.d. and its subsidiaries. The Barr Group of companies markets more than 120 generic and 26 proprietary products in the U.S. and more than 1,200 products globally outside of the U.S. For more information, visit http://www.barrla
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
2. FDA Approves Orphan Drug Status for Revolutionary Cancer Drug for Children
3. FDA Approves AstraZenecas SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
4. FDA Approves Fougeras Clotrimazole Cream USP 1%
5. FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting
6. USDA Approves Syngenta and John Deere for Broadened Biotechnology Endorsement for Corn Crop Insurance
7. Signalife Board Approves Merger
8. FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions
9. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
10. FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents
11. FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Boston Scientific Corporation (NYSE: BSX ) today ... billion aggregate principal amount of its senior notes under ... consists of $850 million of 4.50 percent notes due ... January 2020 and $300 million of 7.375 percent notes ... the net proceeds for general corporate purposes, including prepaying ...
(Date:12/14/2009)... , - Results From a Survey ... in Seven Major Industrialized Countries , , ... their disease, impacts their enjoyment ... with rheumatoid arthritis find shopping for gifts, ... most, difficult to do, ...
(Date:12/11/2009)... College researchers have observed the "hot electron" effect in ... harvested the elusive charges using ultra-thin solar cells, opening ... authors report in the current online edition of ... in solar cells, it generates free electrons in a ... these charges, the electrons must reach the bottom of ...
(Date:12/11/2009)... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY ... appointment of Dr. Alan Warrander to the role ... Development. ,, "Dr. Warrander will be responsible for ... REOLYSIN(R)," said Dr. Brad Thompson, President and CEO ... design of a Phase 3 trial examining REOLYSIN ...
Breaking Biology Technology:Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 2Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 4Elusive 'hot' electrons captured in ultra-thin solar cells 2Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 2Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 3
... the association for,Michigan,s biosciences industry, welcomed nearly 500 ... Expo on Tuesday and Wednesday of,this week at ... The MichBio Expo is,the premier annual gathering of ... attracted 56 exhibitors. The 2009 Expo is,planned for ...
... Center is First Integrated Knowledge Center Outside the United States. ... ... opened the DuPont Knowledge Center (DKC) today, 17 months after breaking ... Knowledge Park in the city’s Genome Valley, the center will be ...
... Nov. 21 Eli Lilly and,Company (NYSE: LLY ... today,announced the successful completion of the previously announced tender offer,by ... ImClone at a price of $70.00 per share in cash. ... 20, 2008. , The ...
Other Biology Technology:MichBio Expo Draws Nearly 500 Professionals; Career Day Raises Profile 2MichBio Expo Draws Nearly 500 Professionals; Career Day Raises Profile 3DuPont Opens Research & Development Center in India 2DuPont Opens Research & Development Center in India 3Lilly Completes Cash Tender Offer for ImClone Systems 2Lilly Completes Cash Tender Offer for ImClone Systems 3
(Date:12/14/2009)... sneezing, touching, or for Tasmanian devils biting ... have driven the dinosaurs to extinction through the transmission ... of f1000 Biology, highlights the ,paleobiological detective work, of ... led them to deduce that a protozoan parasite was ... many tyrannosaurid fossils. , The parasite,s modern-day equivalent, which ...
(Date:12/14/2009)... team of researchers from the Astrobiology Centre (INTA-CSIC) has ... essential to the formation of the most basic biological ... In order to carry out this study, published in ... recreated the chemical conditions of the early Earth. , ... in ammoniac solutions it produces hydrogen cyanide, a substance ...
(Date:12/14/2009)... in preventing some of the stresses of open surgery on ... and organ dysfunction. Laparoscopy is a type of surgery in ... , By adding another gas to the carbon dioxide used ... University Medical Center have found they can preserve more normal ... nitrite (ENO) helped to open blood vessels and keep blood ...
Breaking Biology News(10 mins):Prussian blue linked to the origin of life 2Gas improves blood flow and organ status during minimally invasive surgery 2Cardiogenesis Reports Third Quarter 2009 Results 6149 1Cardiogenesis Reports Third Quarter 2009 Results 6149 2Cardiogenesis Reports Third Quarter 2009 Results 6149 3Cardiogenesis Reports Third Quarter 2009 Results 6149 4Cardiogenesis Reports Third Quarter 2009 Results 6149 5Cardiogenesis Reports Third Quarter 2009 Results 6149 6Cardiogenesis Reports Third Quarter 2009 Results 6149 7Neuro Kinetics Statement Concerning Newspaper Article 6147 1Neuro Kinetics Statement Concerning Newspaper Article 6147 2Neuro Kinetics Statement Concerning Newspaper Article 6147 3Vion Pharmaceuticals Reports 2009 Third Quarter and Nine Month Results 6145 1Vion Pharmaceuticals Reports 2009 Third Quarter and Nine Month Results 6145 2Vion Pharmaceuticals Reports 2009 Third Quarter and Nine Month Results 6145 3Vion Pharmaceuticals Reports 2009 Third Quarter and Nine Month Results 6145 4Vion Pharmaceuticals Reports 2009 Third Quarter and Nine Month Results 6145 5Vion Pharmaceuticals Reports 2009 Third Quarter and Nine Month Results 6145 6
... enzyme can soothe over-excited receptors in the brain, say ... and other neurodegenerative diseases. , Lead author Michel Baudry ... Wei Xu and collaborators from the University of British ... of Neuron. , The researchers injected laboratory ...
... discoverers of the unique mouse line that is resistant to ... and found that white blood cells in these mice overwhelm ... Cancer Immunity, a journal of the Academy of Cancer Immunology, ... C. Willingham, M.D., of Wake Forest University School of Medicine ...
... return severely failing hearts to their normal function, potentially ... research. , The mechanical devices, known as Left Ventricular ... very severe heart failure whilst they await transplantation. The ... Medicine, shows that using an LVAD combined with certain ...
Other Biology News:Decoy pill saves brain cells 2White blood cells of cancer-resistant mice overwhelm natural defenses of cancer cells 2Mechanical 'artificial hearts' can remove need for heart transplant by returning heart to normal 2